Key Highlights

  • The third-quarter 2026 net loss was USD 34.4 million, or USD 0.52 per share, against USD 21.1 million, or USD 0.40 per share, a year earlier, as non-cash Warrant items outweighed lower operating costs.
  • A USD 12.8 million change in the Fair Value of a warrant Liability and USD 2.3 million of offering costs allocated to warrants pushed other expense to USD 14.3 million.
  • Operating expenses fell to USD 20.1 million from USD 22.5 million, with Research and Development at USD 16.1 million and general and administrative costs at USD 4.0 million.
  • Cash, cash equivalents and marketable securities were USD 108.5 million at September 30, 2026, and management concluded there is no longer substantial doubt about continuing as a going concern.

Warrant Accounting Turns a Narrower Operating Loss Into a Wider Net Loss

PMV Pharmaceuticals (NASDAQ:PMVP) filed its Quarterly Report on November 10, 2026. The clinical-stage company develops small molecule therapies aimed at correcting mutant p53 proteins, a mutation found in roughly half of all cancers, and has no revenue. Its loss from operations improved to USD 20.1 million from USD 22.5 million, yet the net loss widened to USD 34.4 million. The gap came from the common stock warrants issued in its August 2026 offering, which are classed as a liability and remeasured each quarter. A rise in their fair value is booked as a loss, here USD 12.8 million, plus USD 2.3 million of offering costs expensed. Interest income also dropped to USD 0.8 million from USD 1.5 million.

USD 50.8 Million Raise Reshapes the Balance Sheet

The offering closed on September 2, 2026 and sold 22,055,000 shares plus pre-funded warrants for 19,900,000 shares, with accompanying warrants for 41,955,000 shares. Gross proceeds were about USD 50.8 million and net proceeds about USD 46.9 million. The warrants carry an initial exercise price of USD 1.21 a share. Their terms include a reset after the FDA announces whether it accepts the rezatapopt application for review: the price would fall to the greater of 33% of the initial price or a recent average market price, with the share count rising to keep aggregate exercise value unchanged. That feature can add dilution and keep the fair-value charge volatile. Nine-month net loss was USD 70.5 million, or USD 1.22 per share, against USD 1.14.

Rezatapopt Filing Plan Anchors the Cash Runway

Substantially all research spending relates to rezatapopt, a candidate for tumors with a p53 Y220C mutation. Enrollment of platinum-resistant or refractory ovarian cancer patients for the primary analysis of the Phase 2 monotherapy portion is complete, and the company plans to submit its first New Drug Application under Accelerated Approval in the first quarter of 2027. Nine-month operating cash use was USD 52.4 million, compared with USD 56.4 million a year earlier. Management said the cash balance should fund planned operations for at least one year, but warned it expects costs to rise as it prepares for approval and possible commercialization. It also has no sales force and no approved product, and the accumulated Deficit stands at USD 517.0 million.

Where Things Stand

The wider loss came from accounting for new warrants, not from higher spending. PMV Pharmaceuticals (NASDAQ:PMVP) cut operating expenses to USD 20.1 million, but a USD 12.8 million fair-value charge and USD 2.3 million of offering costs lifted the net loss to USD 34.4 million. The USD 108.5 million cash position removed the going-concern doubt for now. The next markers are the planned application in the first quarter of 2027, the FDA acceptance decision that triggers the warrant reset, and later warrant remeasurement.